The current study explored the potential links between breast cancer and human interferon α-2b (hIFNα-2b) gene mutations. The hIFNα-2b gene was amplified from breast cancer tumor tissue samples (N = 60) by polymerase chain reaction (PCR) and the products were subjected to gene sequencing. A total of 38 (63.3%) samples showed positive PCR amplification results. Several of these also exhibited frequent alterations (mutations) after 400 bp and, in particular, adenine was replaced by other bases. A total of 19 selected mutated amino acids were analyzed for local/general fold pattern changes. Human IFNα-2b receptor (IFNAR): ligand (hIFNα-2b protein) interactions through a Z-DOCK (3.0.2) server were also evaluated to assess the binding patterns of each ligand to receptor to induce Janus-Kinase-signal transducer and activator of transcription antiproliferative signal transduction pathway inside the cancer cells. Certain local structural and conformational changes were predicted to be induced by mutations in the ligand. The variant models of the hIFNα-2b displayed structural and conformational changes that signified that changes to hIFNα-2b may be a risk factor in addition to other known factors associated with onset/progression of female breast carcinoma. It was hoped that others might build upon the research in this study evaluating protein structural models with mutations and their consequent interactions with receptors in the development of potent immune therapeutic drugs for breast cancer that are based on recombinant hIFNα-2b.
Get full access to this article
View all access options for this article.
References
1.
AhmedF, MahmudS, HatcherJ, et al.Breast cancer risk factor knowledge among nurses in teaching hospitals of Karachi, Pakistan: A cross-sectional study. BMC Nursing, 2006; 5:6.
2.
Al-MansouriLJ, AlokailMS. Molecular basis of breast cancer. Saudi Med J, 2006; 27:9–16.
3.
FerlayJ, SoerjomataramI, ErvikM, DikshitR, EserS, MathersC, RebeloM, ParkinDM, FormanD, BrayF. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr (accessed July5, 2016).
4.
JemalA, CenterMM, DeSantisC, et al.Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 2010; 19:1893–1907.
5.
FerlayJ, SoerjomataramI, DikshitR, et al.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Intl J Cancer, 2015; 136:E359–E386.
6.
BhurgriY, BhurgriA, HassanSH, et al.Cancer incidence in Karachi, Pakistan: First results from Karachi cancer registry. Intl J Cancer, 2000; 85:325–329.
7.
PikeMC, SpicerDV, DahmoushL, et al.Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev, 1993; 15:17–35.
8.
MettlinC. Global breast cancer mortality statistics. Cancer J Clinicians, 1999; 49:138–144.
9.
CaporasoN, GoldsteinA. Issues involving biomarkers in the study of the genetics of human cancer. IARC Sci Publ, 1996; 54:237–250.
10.
RussoJ, HuY, YangX, et al.Developmental, cellular, and molecular basis of human breast cancer. JNCI Monogr, 2000; 27:17–37.
11.
Mariani-CostantiniR, EscotC, TheilletC, et al.In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res, 1988; 48:199–205.
12.
HuangE, ChengSH, Dressman, PittmanHJ, et al.Gene expression predictors of breast cancer outcomes. Lancet, 2003; 361:1590–1596.
13.
BalachandranS, KimCN, YehWC, et al.Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J, 1998; 17:6888–6902.
14.
ShtrichmanR, SamuelCE. The role of IFNγ in anti-microbial immunity. Curr Opin Microbiol, 2001; 4:251–259.
15.
DarnellJE. STATs and gene regulation. Science, 1997; 277:1630–1635.
16.
UddinS, MajchrzakSB, WoodsonJ, et al.Activation of the p38 mitogen-activated protein kinase by Type I interferons. J Biol Chem, 1999; 274:30127–30131.
17.
MogensenK, LewerenzM, ReboulJ, et al.Type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res, 1999; 19:1069–1098.
18.
ShahidS, MahmoodN, ChaudhryMN, et al.Mutations of the human interferon α2b (hIFNα2b) gene in occupationally-protracted low-dose radiation-exposed personnel. Cytokine, 2015a;73:181–189.
19.
ShahidS, ChaudhryMN, MahmoodN. Sheikh S. Mutations of the human interferon α2b gene in brain tumor patients exposed to different environmental conditions. Cancer Gene Ther, 2015b;22:246–261.
20.
ShahidS, ChaudhryMN, MahmoodN. Mutations of human interferon α2b (hIFNα2b) gene in cancer patients receiving radiotherapy. Am J Cancer Res, 2015c;5:2455.
21.
BrierleyMM, FishEN. Review: IFNα/β receptor interactions to biologic outcomes: Understanding the circuitry. J Interferon Cytokine Res, 2002; 22:835–845.
22.
ParmarS, PlataniasLC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol, 2003; 15:431–439.
23.
Interferon Monograph. BC Cancer Agency Cancer Drug Manual. 2015. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Interferon_monograph_1June2015.pdf (accessed July5, 2016).
24.
SabaR, JabbourE, GilesF, et al.IFNα therapy for patients with essential thrombocythemia. Cancer, 2005; 103:2551–2557.
25.
MahmoodN, AkhtarM, RashidN. (eds.) Cloning expression and mutational analysis of human interferon α2: (IFNα2) gene and isolation of anti-viral gene sequences. In: Cloning Expression and Mutational Analysis of Human Interferon α2. Berlin: VDM (Verlag Dr. Muller). 2011. pp. 20–21.
26.
Critchley-ThorneR, YanN, NacuS, et al.Down-regulation of the interferon signaling pathway in T-lymphocytes from patients with metastatic melanoma. PLoS Med, 2007; 4:e176.
27.
DiazMO, RubinCM, HardenA, et al.Deletions of interferon genes in acute lymphoblastic leukemia. New Engl J Med, 1990; 322:77–82.
28.
HuL, ZaloudekC, MillsG, et al.In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res, 2000; 6:880–886.
29.
ElledgeRM, AllredDC. p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat, 1994; 32:39–47.
30.
ChangJ, WootenE, TsimelzonA, et al.Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003; 362:362–369.
31.
KeenJC, DavidsonNE. The biology of breast carcinoma. Cancer, 2003; 97:825–833.
32.
BoukerKB, SkaarTC, RigginsRB, et al.Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis, 2005; 26:1527–1535.
33.
Staveley-O'CarrollK, SotomayorE, MontgomeryJ, BorrelloI, et al.Induction of antigen-specific T-cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA, 1998; 95:1178–1183.
34.
IndraccoloS, GolaE, RosatoA, et al.Differential effects of angiostatin, endostatin and IFNα1 gene transfer on in vivo growth of human breast cancer cells. Gene Ther Basingstoke, 2002; 9:867–878.
35.
ZitvogelL, ApetohL, GhiringhelliF, et al.The anti-cancer immune response: Indispensable for therapeutic success?. J Clin Invest, 2008; 118:1991–2001.
36.
LeePP, YeeC, SavagePA, et al.Characterization of circulating T-cells specific for tumor-associated antigens in melanoma patients. Nat Med, 1999; 5:677–685.
37.
WeberJ, SondakVK, ScotlandR, et al.Granulocyte-macrophage–colony-stimulating factor added to a multi-peptide vaccine for resected Stage II melanoma. Cancer, 2003; 97:186–200.
38.
ZouW. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 2005; 5:263–274.
39.
RabinovichGA, GabrilovichD, SotomayorEM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol, 2007; 25: 267–296.
40.
SolimanH. Immunotherapy strategies in the treatment of breast cancer. Cancer Control, 2013; 20:17–21.
41.
BourlaA, ZamarinD. Immunotherapy: New strategies for treatment of gynecologic malignancies. Oncology (in press). 2016; 30:59–66, 69.
42.
RosenbergSA, LotzeMT, YangJC, et al.Combination therapy with IL-2 and IFNα for treatment of patients with advanced cancer. J Clin Oncol, 1989; 7:1863–1874.
43.
ReiterZ. Interferon—a major regulator of natural killer cell-mediated cytotoxicity. J Interferon Res, 1993; 13:247–257.
44.
Critchley-ThorneRJ, SimonsDL, YanN, et al.Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A, 2009; 106:9010–9015.
45.
KirkwoodJ, RichardsT, ZarourH, et al.Immunomodulatory effects of high-dose and low-dose IFN-α2b in patients with high-risk resected melanoma. Cancer, 2002; 95:1101–1112.
